Lisocabtagene Maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie
[]
pfs and dor curves, by best response and mrd negativity
- unsurprisingly those who achieved responses did better; those who achieved crs did the best
- there is a (small) group of responders who appear to have durable remissions
#asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem